؉ T-cell response, plays a critical role in providing protective immunity following infection with the Old World arenaviruses LASV and LCMV. In the current study, we evaluated whether HLA class I-restricted epitopes that are cross-reactive among pathogenic arenaviruses could be identified for the purpose of developing an epitope-based vaccination approach that would cross-protect against multiple arenaviruses. We were able to identify a 
Arenaviruses are a family of rodent-borne viruses that are associated with severe disease in humans. Phylogenetically, the arenaviruses are organized into Old World or New World groups, with a subdivision of the New World viruses falling into three distinct lineages (A to C) (17) . At least eight arenaviruses are known to cause human disease. Of the New World viruses, Junin virus (JUNV), Machupo virus (MACV), Guanarito virus (GTOV), and Sabia virus (SABV) (all members of lineage B) are etiologic agents of hemorrhagic fever syndromes in South America, while Whitewater Arroyo virus (WWAV) (lineage A) has been linked to two fatalities in North America (13, 17) . Lassa virus (LASV), Lujo virus, and lymphocytic choriomeningitis virus (LCMV) represent the Old World viruses that cause disease in humans (10, 13) . LASV and Lujo virus, both of which are found in Africa, can cause hemorrhagic fevers, while LCMV infection, which is endemic throughout the world, can result in aseptic meningitis in immunocompetent individuals (10, 15, 33) . LCMV is also a potent teratogen responsible for outcomes such as hydrocephaly and chorioretinitis in developing fetuses (3-5, 31, 36) or high lethality in immunosuppressed patients (20) . LASV, LCMV, JUNV, GTOV, and MACV are NIAID category A agents, and with the exception of LCMV, each of these viruses is also on the CDC select agent list of potential bioterrorism threat agents.
At present, vaccines for the prevention of human arenavirus disease are limited to a single live attenuated vaccine (Candid 1) for the prevention of JUNV infection. JUNV Candid 1, which is classified as an investigational new drug in the United States, was derived from the wild-type (WT) JUNV strain XJ13 through serial passage both in vivo and in vitro (22) . The only antiviral agent currently utilized for treatment of a subset of arenavirus infections is ribavirin (23, 35) . Passive antibody therapy has been effective in reducing mortality associated with Argentine hemorrhagic fever caused by infection with JUNV (19, 32) .
Arenaviruses have an RNA genome that is encoded in an ambisense fashion and consists of two single-stranded RNA segments, the ϳ3-kb small (S) segment and ϳ7-kb large (L) segment. The arenavirus proteome consists of four proteins: the viral RNA-dependent RNA polymerase (L) and zinc binding protein, which are encoded on the L segment, and the S segment-encoded nucleoprotein (NP) and glycoprotein pre-cursor (GPC), which is posttranslationally modified to yield a stable signal peptide, GP1, and GP2 (49) . GP1 and GP2 form heterodimers that facilitate entry into permissive host cells through an interaction with either ␣-dystroglycan for the Old World viruses LASV and LCMV (i.e., for strain clone 13 but not strain Armstrong 53b) (16, 30) or transferrin receptor 1 for a subset of the pathogenic New World arenaviruses (1, 41, 42) . GP1 is also the target of antiviral neutralizing antibodies (nAbs) (11) . The NP and L protein, which are encoded in negative or antimessage sense, are the first proteins to be expressed following infection, whereas the GPC and zinc binding protein, which are encoded in positive or message sense, arise later, demonstrating the temporal control of gene expression that is inherent in arenavirus replication.
The cellular immune response, specifically the CD8 ϩ T-cell response, is important for the development of protective immunity following arenavirus infection (for a review, see reference 9). This is particularly true for the pathogenic Old World arenaviruses LCMV and LASV, as high-quality antiviral nAbs typically do not form following infection with these viruses; low-titer nAbs, if formed, usually appear weeks to months following clearance of the primary infection (11, 14, 18, 21, 34) . In the case of LCMV, it was recently shown that the GPC itself, not the viral backbone, is responsible for this poor nAb response (40) . This observation has important implications for vaccine design, as delivery of Old World arenavirus GPCs in even the most immunogenic of vectors may not improve the kinetics or magnitude of nAb formation following immunization. Therefore, vaccine development strategies for Old World arenaviruses must necessarily focus on the induction of protective cellular immune responses. In contrast, New World arenaviruses such as JUNV and MACV are able to induce both high-quality cellular and humoral immune responses following infection (39) .
A significant challenge currently facing vaccine development is pathogen heterogeneity. In the case of arenaviruses, the low incidence of disease observed for the majority of these antigenically diverse viruses combined with the low socioeconomic status of the countries where they are endemic makes it unlikely that individual vaccines will be developed for each of the eight pathogenic arenaviruses. Therefore, the development of multivalent vaccines capable of providing cross-protection against multiple pathogenic arenavirus family members is desirable. It has been well-established that CD8 ϩ T-cell epitopes are effective vaccine determinants for arenaviruses (6, 8, 25, 29, 43, 44) and that cross-protective cellular immune responses are generated following arenavirus infection in animal models (39, 43) . In the current study, we evaluated whether HLA class I-restricted epitopes that are cross-reactive among pathogenic arenavirus species could be identified for the purpose of developing an epitope-based, multivalent vaccination approach that would cross-protect against multiple arenaviruses.
MATERIALS AND METHODS
Amino acid sequence analyses. The arenavirus open reading frames utilized in this study were those encoding LASV strain Josiah GPC (NCBI accession number NP_694870), LCMV strain Armstrong 53b GPC (NCBI accession number NP_694851), MACV strain Carvallo GPC (NCBI accession number AAN05425), JUNV strain MC2 GPC (NCBI accession number BAA00964), GTOV strain INH-95551 GPC (NCBI accession number AAN05423), SABV strain SPH114202 GPC (NCBI accession number AAC55091), WWAV strain AV9310135 GPC (NCBI accession number AAK60497), and Pichinde virus (PICV) strain Munchique GPC (NCBI accession number AAC32281).
Peptides. Peptides (Ն90% pure) were obtained from Genemed Synthesis, Inc. (South San Francisco, CA). Each peptide was purified by high-performance liquid chromatography (HPLC), and the sequence was verified by mass spectrometry. Hepatitis B virus (HBV) ENV 378 (LLPIFFCLWV) was used as an irrelevant, HLA-A*0201-restricted peptide.
MHC-peptide binding assays. Major histocompatibility complex (MHC) molecules were purified and binding assays were performed, as previously described (47, 48) . Briefly, 1 to 10 nM radiolabeled peptide was coincubated with 1 M to 1 nM purified MHC in the presence of 1 to 3 M human ␤ 2 -microglubulin. After 2 days, binding of the radiolabeled peptide to the corresponding MHC class I molecule was determined by capturing MHC-peptide complexes on Greiner Lumitrac 600 microplates (Greiner Bio-One, Longwood, FL) coated with the W6/32 antibody and measuring bound counts per minute using a TopCount microscintillation counter (Packard Instrument Co.).
Mice. HLA-A*0201/K b (referred to as HLA-A*0201 throughout) transgenic mice were bred at The Scripps Research Institute (TSRI). These mice represent the F1 generation, resulting from a cross between HLA-A*0201/K b transgenic mice (that express a chimeric gene consisting of the ␣1 and ␣2 domains of HLA-A*0201 and the ␣3 domain of H-2K b ) created on the C57BL/6 background and BALB/c mice (The Jackson Laboratory) (53) . All studies were conducted in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care and according to Institutional Animal Care and Use Committee-approved animal protocols.
Cells. JA2.1 cells (human Jurkat cells that express the HLA-A*0201/K b chimeric gene) (53) were grown as previously described (46) .
Viruses. LCMV infections were conducted using strain Armstrong 53b. This virus was expanded in BHK-21 cells, and the titers of the virus were determined on Vero E6 cells. vvLASV-GPC and vvLCMV-GPC (which express LASV strain Josiah GPC and LCMV Armstrong 53b GPC, respectively) are recombinant vaccinia viruses (rVV) that were generated on the Western Reserve (WR) background as previously described (6, 54) .
Immunizations and viral challenges. were cultured with 1 ϫ 10 5 peptide-pulsed or rVV-infected JA2.1 target cells. Target cells were pulsed by incubating them with peptide for at least 2 h at room temperature, followed by three washes to remove free peptide. For rVV infections, JA2.1 cells were infected (multiplicity of infection of 10) 18 h prior to the assay. Effector and target cells were incubated in flat-bottom 96-well nitrocellulose plates (Immobilon-P membrane; Millipore) precoated with 50 l/well of anti-gamma interferon (anti-IFN-␥) monoclonal antibody (MAb) (10 g/ml Mabtech AN18). After 16 to 20 h, plates were washed and wells were incubated with 100 l biotinylated anti-IFN-␥ MAb (1 g/ml Mabtech R4-6A2) for 2 h. After additional washing, spots were developed by sequential incubation with Vectastain ABC peroxidase (Vector Laboratories) and 3-amino-9-ethyl carbazole solution (Sigma-Aldrich) and counted by computer-assisted image analysis (Zeiss KS ELISPOT reader).
Each assay was performed in 3 replicate wells, and the experimental values were expressed as the mean spots/ Statistical analyses. To evaluate whether a CD8 ϩ T-cell response to peptidepulsed or rVV-infected target cells was statistically significant, we utilized the Student t test to compare mean IFN-␥ spots generated by CD8 ϩ T cells in response to JA2.1 cells pulsed with peptide (relevant versus irrelevant) and those infected with an rVV construct (relevant versus irrelevant). To determine whether immunization with a given epitope led to viral titer reduction in the spleen following i.p. challenge, we used the Student t test.
RESULTS

Identification of candidate HLA-A*0201-restricted epitopes that are cross-reactive among arenavirus family members.
The primary goal of our study was to determine whether highly conserved, cross-reactive human CD8 ϩ T-cell epitopes exist among pathogenic arenaviruses and, if so, to determine whether they could be successfully utilized as multivalent vaccine determinants to provide cross-protection against heterologous arenavirus infection. In previous studies, we had identified HLA-A*0201-restricted epitopes derived from Old World arenaviruses LCMV (GPC [447] [448] [449] [450] [451] [452] [453] [454] [455] ) and LASV (GPC [42] [43] [44] [45] [46] [47] [48] [49] [50] and GPC [60] [61] [62] [63] [64] [65] [66] [67] [68] ) that were protective against viral challenge following peptide immunization of HLA-A*0201 mice (6, 8) . To evaluate whether these protective epitope sequences would be conserved among diverse arenaviruses and therefore serve as candidates for multivalent vaccination, we conducted sequence alignments comparing each linear epitope sequence to its corresponding region in other Old World and New World arenavirus family members. None of the epitopes examined shared 100% sequence homology with other arenaviruses (Table 1 and data not shown). We did, however, identify a panel of peptide sequences corresponding to LCMV GPC 447-455 that differed from this epitope by 1 to 4 amino acids and contained permissive HLA-A2 supertype B-and F-pocket anchor residues at positions 2 and 9, respectively ( Table 1) . The highest degree of sequence conservation was found between LCMV GPC 447-455 and LASV GPC [441] [442] [443] [444] [445] [446] [447] [448] [449] , where a single, conservative Val-to-Ile substitution was observed at position 3. Greater diversity in primary sequence (range, 2 to 4 amino acid substitutions) was found between LCMV GPC 447-455 and the corresponding peptides found in the New World arenaviruses.
Next, to examine the breadth of HLA coverage afforded by this panel of arenavirus peptides, we measured the binding affinities of these peptides to common HLA-A2 supertype alleles (HLA-A*0201, -A*0202, -A*0203, -A*0206, and -A*6802). To determine binding affinity, each peptide was mixed with a radioactively labeled control peptide and coincubated with purified MHC as described in Materials and Methods. High-affinity binding (defined here as a 50% inhibitory concentration [IC 50 ] less than or equal to 100 nM) to 3 or more HLA-A2 supertype alleles was observed for each peptide (Table 1). Binding affinity to purified HLA-A*0201 ranged from 10 nM for PICV GPC 455-463 to 326 nM for JUNV GPC 429-437 / MACV GPC [429] [430] [431] [432] [433] [434] [435] [436] [437] . These data indicate that this set of arenavirus peptides has the potential to provide broad population coverage. CD8 ؉ T cells from HLA-A*0201 mice infected with LCMV cross-reactively kill APC pulsed with Old World and New World arenavirus peptides. Next, we wished to determine whether the candidate peptides we had identified from pathogenic arenaviruses (LASV GPC 441-449 , LCMV GPC 447-455 , MACV GPC 444-452 , JUNV GPC 429-437 , GTOV GPC 427-435 , and WWAV GPC 428-436 ) would be cross-reactively recognized by CD8 ϩ T cells in the context of an arenavirus infection. To do so, we infected HLA-A*0201 mice with 2 ϫ 10 5 PFU of LCMV strain Armstrong by i.p. inoculation and 7 days later screened these animals for in vivo CTL killing of syngeneic, CFSE-labeled target cells that had been pulsed with an arenavirus peptide (CFSE hi ) or an irrelevant peptide (CFSE lo ). We observed significant levels of specific killing against antigenpresenting cells (APC) pulsed with the homologous LCMV peptide GPC [447] [448] [449] [450] [451] [452] [453] [454] [455] (range, 70 to 95%) as well as targets pulsed with heterologous arenavirus peptides, including LASV GPC 441-449 (range, 96 to 97%), GTOV GPC 427-435 (range, 60 ؉ T-cell responses to heterologous peptides. To determine whether the identified peptides could induce cross-reactive CD8 ϩ T-cell responses in vivo and thus be used as vaccine candidates, groups of HLA-A*0201 mice were immunized with individual candidate peptides via s.c. inoculation as described in Materials and Methods. CD8 ϩ T cells were isolated at 11 to 14 days postimmunization and exposed to JA2.1 target cells that had been pulsed with decreasing serial 20-fold doses (range, 1 ϫ 10 Ϫ5 to 6.25 ϫ 10 Ϫ11 M) of each candidate peptide in an ex vivo IFN-␥ ELISPOT assay. A given dose was considered immunogenic if it induced IFN-␥ spot formation that was significantly higher than the observed response to an identical dose of an irrelevant, HLA-A*0201-restricted peptide.
Following immunization, high-avidity CD8 ϩ T-cell responses (endpoint reactivity range, 1 ϫ 10 Ϫ9 to 6.25 ϫ 10 Ϫ11 M) were observed against each immunizing peptide, with the exception of JUNV GPC 429-437 /MACV GPC 429-437 (endpoint, 1 ϫ 10 Ϫ5 M) ( Fig. 2A to F) . Binding affinity for HLA-A*0201 correlated with CD8 ϩ T-cell avidity as immunizing peptides that bound HLA-A*0201 with IC 50 s of 10 to 49 nM induced high-avidity CD8 ϩ T-cell responses (endpoint, 1 ϫ 10 Ϫ9 M or less), while the JUNV GPC 429-437 /MACV GPC [429] [430] [431] [432] [433] [434] [435] [436] [437] peptide that bound at 326 nM led to a low-avidity response (endpoint, 1 ϫ 10 Ϫ5 M). Variable patterns of CD8 ϩ T-cell cross-reactivity were observed following peptide immunization. For example, following immunization with the Old World peptides LASV GPC [441] [442] [443] [444] [445] [446] [447] [448] [449] and LCMV GPC 447-455 , nearly identical high-avidity CD8 ϩ T-cell responses to both the immunizing peptide and the corresponding heterologous Old World peptide were observed in each case ( Fig. 2A and B) . Detectable responses were also observed against a subset of the New World peptides in these animals, including PICV GPC 455 ϩ T-cell responses were observed against a subset of the New World peptides in each case while crossreactive responses to the Old World peptides, while detectable, were of lower avidity and frequency (Fig. 2D to F) . For example, following immunization with GTOV GPC 427-435 , the MACV GPC 444-452 /JUNV GPC 429-437 and WWAV GPC [428] [429] [430] [431] [432] [433] [434] [435] [436] peptides were recognized by CD8 ϩ T-cell responses with frequencies and avidities similar to those seen against the immunizing GTOV GPC 427-435 peptide, while PICV GPC 455-463 was not recognized (Fig. 2D) . The LASV GPC 441-449 and LCMV GPC 447-455 peptides were recognized in these animals, but the responses to these peptides were of lower magnitude and avidity (endpoint reactivity, 2.5 ϫ 10 Ϫ8 M). WWAV GPC 428-436 -primed CD8 ϩ T cells recognized each of the heterologous peptides screened, but IFN-␥ spot formation was ϳ10-fold lower than that of the immunizing peptide, and only the GTOV GPC 427-435 and PICV GPC 455-463 peptides induced significant responses at 1 ϫ 10 Ϫ9 M (Fig. 2E) . Finally, following PICV GPC 455-463 immunization, heterologous peptides induced low-avidity CD8 ϩ T-cell responses (endpoint range, 1 ϫ 10 Ϫ5 to 2.5 ϫ 10 Ϫ8 M) of relatively low magnitude.
Cross-reactive CD8
؉ T-cell recognition of naturally processed peptides from native LASV GPC or LCMV GPC expressed in HLA-A*0201-restricted human APC. Because the strongest cross-reactive CD8 ϩ T-cell responses were observed among the Old World epitopes LASV GPC 441-449 and LCMV GPC 447-455 following peptide immunization (Fig. 2) , we focused on addressing the suitability of these two peptides as vaccine candidates for the remainder of the study. One important consideration was whether these peptides could be pro- cessed from their native viral antigens by human APC and presented to CD8 ϩ T cells that had been primed with either LASV GPC 441-449 or LCMV GPC [447] [448] [449] [450] [451] [452] [453] [454] [455] . To express native arenavirus GPC proteins within human APC, we infected JA2.1 cells with rVV encoding the full-length LASV GPC (vvLASV-GPC) or LCMV GPC (vvLCMV-GPC) (see Materials and Methods). To assess epitope processing and CD8 ϩ T-cell recognition of presented peptides, splenic CD8 ϩ T cells from HLA-A*0201 mice that had previously been immunized with LASV GPC 441-449 or LCMV GPC 447-455 were screened for IFN-␥ secretion in response to JA2.1 cells that had been either pulsed with peptide (irrelevant A*0201-restricted peptide, LASV GPC 441-449 , or LCMV GPC 447-455 ) or infected with VV (vvWT, vvLASV-GPC, or vvLCMV-GPC) (Fig. 3) . Both LASV GPC 441-449 -primed (Fig. 3A) and LCMV GPC 447-455 -primed (Fig. 3B) CD8 ϩ T cells generated significant levels of IFN-␥ spots following exposure to JA2.1 cells that expressed the homologous and heterologous GPC proteins, respectively, confirming that cross-reactive recognition of naturally processed peptides occurs in the context of human APC.
Cross-reactive in vivo CTL killing following peptide immunization. We next wished to evaluate whether peptide immunization of HLA-A*0201 mice with LCMV GPC [447] [448] [449] [450] [451] [452] [453] [454] [455] Figure 5A outlines the logistics of the challenge experiment. Groups of HLA-A*0201 mice (n ϭ 5 per group) were immunized with LASV GPC 441-449 , LCMV GPC 447-455 , or adjuvant alone (control group). LCMV GPC 447-455 served as a positive control for this experiment. On day 14 postimmunization, mice were challenged with 2 ϫ 10 5 PFU of LCMV via i.p. inoculation. Spleens were harvested from each mouse on day 4 postchallenge and screened for LCMV titer (Fig. 5B ) and epitope-specific CD8 ϩ T cells (Fig. 5C) . Each of the control animals (adjuvant alone) displayed evidence of high-titer LCMV replication following challenge (Fig. 5B) . As expected, prior immunization with LCMV GPC 447-455 led to a significant decrease (85%; P ϭ 0.004) in mean viral titer compared to that in control animals. We also observed a significant reduction in mean viral titer
FIG. 3. CD8
ϩ T-cell recognition of naturally processed peptides from native LASV GPC or LCMV GPC expressed in HLA-A*0201-restricted human APC. HLA-A*0201 mice were immunized with either LASV GPC 441-449 (A) or LCMV GPC 447-445 (B) as indicated above each graph. Splenic CD8 ϩ T cells were isolated 11 to 14 days later and exposed to JA2.1 cells that had been pulsed with peptide (LASV GPC 441-449 , LCMV GPC 447-445 , or irrelevant peptide) or infected with either wild-type VV (vvWT) or an rVV that expresses the native LASV GPC (vvLASV-GPC) or LCMV GPC (vvLCMV-GPC) in an ex vivo IFN-␥ ELISPOT assay. Peptides or rVVs were considered immunogenic if they induced IFN-␥ spot formation that was significant compared to that on JA2.1 target cells that had been pulsed with an irrelevant HLA-A*0201-restricted peptide or infected with vvWT. Immunogenic responses are denoted by an asterisk. following immunization with the heterologous peptide LASV GPC 441-449 (92% reduction; P ϭ 0.005).
Protection correlates with expansion of epitope-specific CD8 ؉ T cells. We next wished to determine whether an expansion of CD8 ϩ T cells specific for LCMV GPC 447-455 and/or LASV GPC 441-449 would correlate with the protection observed in Fig. 5B . To do so, for each challenge group (LCMV GPC 447-455 -immunized, LASV GPC 441-449 -immunized, or adjuvant only-immunized mice), we measured the frequency of splenic CD8 ϩ T cells specific for LCMV GPC 447-455 , LASV GPC 441-449 , or an irrelevant HLA-A*0201-restricted peptide in an IFN-␥ ELISPOT assay. Four days after viral challenge, mice that had previously been immunized with LCMV GPC 447-455 or LASV GPC 441-449 showed a clear expansion of CD8 ϩ T cells that were specific for either of these peptides in each case (Fig. 5C ). In both of these peptide-immunized groups, approximately equal numbers of IFN-␥ spots were formed against LCMV GPC 447-455 and LASV GPC [441] [442] [443] [444] [445] [446] [447] [448] [449] .
DISCUSSION
Arenaviruses are a family of rodent-borne viruses that cause significant human disease throughout the world. Currently, no FDA-approved vaccines exist for the eight antigenically diverse species of arenavirus that are known to cause human disease. Therefore, it is a priority to develop vaccines for the prevention of human disease caused by these pathogens. Considering the large number of arenavirus species that need to be targeted, it would be highly desirable to develop multivalent vaccines that could provide cross-protection against multiple arenavirus species. Over the past several years, our research team has focused on the development of such multivalent vaccines. Our approach has been to capitalize on the known importance of the cellular immune response for providing protective immunity and accordingly to develop epitope-based vaccines capable of inducing protective CD8 ϩ T-cell responses specific to multiple arenaviruses (7). We have tested two strategies to induce multivalent protection: inclusion of protective HLA-restricted epitopes corresponding to each of several targeted arenaviruses in a single vaccine (28) and, alternatively, to reduce the complexity of the vaccine, inclusion of highly conserved, cross-reactive epitopes, each of which has the capacity to induce cross-protection against multiple arenaviruses. In the present study, we have formally demonstrated that highly conserved, cross-reactive human CD8
ϩ T-cell epitopes exist among pathogenic arenaviruses and that they can be successfully utilized as multivalent vaccine determinants to provide cross-protection against heterologous arenavirus infection.
Our finding of heterologous immunity following immunization with an HLA-restricted epitope extends observations initially made by Peters et al. when they demonstrated, in a guinea pig model of arenavirus infection, that heterologous immunity could be induced between several species of Old World arenaviruses (39) . In that study, prior infection of guinea pigs with LCMV or another Old World arenavirus, Mopeia virus (MOPV), provided complete protection against a subsequent challenge with a lethal dose of LASV. Likewise, previous infection with LASV provided protection against subsequent challenge with LCMV. In each case, nAbs specific for the heterologous challenge viruses were not detectable at the time of challenge or viral clearance. Furthermore, adoptive transfer experiments formally demonstrated that splenocytes, but not plasma, were responsible for this heterologous immunity. Finally, lymphocytes from these animals were able to kill syngeneic target cells that had been infected with either the homologous priming virus or the heterologous challenge virus. Similarly, heterologous immunity has also been observed in nonhuman primate models of arenavirus infection. For example, previous infection of nonhuman primates with MOPV provided heterologous protection against a subsequent challenge with LASV despite an absence of nAb to the heterologous challenge virus (39) . While the absence of nAb in the above-mentioned studies strongly suggests that cell-mediated immunity is responsible for providing protective heterologous immunity, it was not formally shown. More recently, however, Rodriguez-Carreno et al. demonstrated that immunization of BALB/c mice with a DNA vaccine encoding a CD8 ϩ T-cell epitope derived from LASV NP was sufficient to confer heterologous protection against LCMV challenge (43) . Likewise, in the present study, we show for the first time that an HLArestricted epitope derived from LASV can induce heterologous protection against LCMV challenge in HLA transgenic mice. These findings confirm that, regardless of the host species' MHC background, CD8
ϩ T-cell responses directed against an epitope that is conserved among arenaviruses is sufficient to provide robust heterologous immunity to antigenically diverse arenavirus species. One potential concern in this study was whether our approach to multivalent vaccination, namely, immunization with a CD8 ϩ T-cell epitope derived from LCMV or LASV, would lead to "original antigenic sin" with regard to the resulting CD8 ϩ T-cell response to the heterologous peptide in each case (either the LASV or LCMV peptide, respectively). The epitopes used as vaccine determinants, LCMV GPC 447-445 and LASV GPC 441-449 , differ from one another by a single, conservative amino acid substitution at position 3 (Table 1) . Klenerman and Zinkernagel had previously demonstrated that original antigenic sin can occur with CD8 ϩ T-cell responses in the murine model of LCMV infection (26) . Specifically, they found that C57BL/6 mice primed with LCMV strain WE generated a CD8 ϩ T-cell response to GPC [33] [34] [35] [36] [37] [38] [39] [40] [41] but that upon secondary challenge with a WE variant containing a mutant GPC [33] [34] [35] [36] [37] [38] [39] [40] [41] epitope (differing from the wild type [WT] by a single, conservative amino acid substitution at position 3), the CD8 ϩ T-cell response was directed against the WT epitope and not the variant epitope. Inversely, a primary infection with the WE variant followed by a secondary challenge with WT WE led to CD8 ϩ T-cell responses that were equal between the WT and mutant epitopes. This same phenomenon was also observed for the H-2 d -restricted peptide, NP 118-126. Based on these observations, Klenerman and Zinkernagel concluded that the CD8 ϩ T-cell response was determined by the original peptide presented and that cross-reactivity was asymmetrical (26) . Therefore, the order in which epitopes are seen can potentially determine the breadth of the response to heterologous peptides that share high levels of amino acid sequence identity. In our study, we clearly show that original antigenic sin does not occur with respect to the peptides LCMV GPC 447-445 and LASV GPC 441-449 as immunization with either peptide leads to virtually identical CD8 ϩ T-cell responses to both the immunizing and heterologous peptides in each case (Fig. 2 to 4) . Likewise, in the challenge assay, previous immunization with LASV GPC 441-449 followed by heterologous LCMV challenge led to equivalent CD8 ϩ T-cell responses against LCMV GPC 447-445 and LASV GPC [441] [442] [443] [444] [445] [446] [447] [448] [449] (Fig. 5) . With that said, immunization of HLA-A*0201 mice with certain New World peptides in our set did not always result in equal CD8 ϩ T-cell responses to both the immunizing peptide and heterologous peptide(s). For example, while immunization with GTOV GPC 427-435 led to a CD8 ϩ T-cell response that was similar in both magnitude and avidity to those of both GTOV GPC 427-435 and WWAV GPC 428-436 , immunization with WWAV GPC 428-436 resulted in a response where the magnitude of CD8 ϩ T cells recognizing WWAV GPC [428] [429] [430] [431] [432] [433] [434] [435] [436] was approximately 10-fold higher than the number of CD8 ϩ T cells recognizing GTOV GPC [427] [428] [429] [430] [431] [432] [433] [434] [435] . Therefore, it is important to verify, for each cohort of crossreactive epitopes, that original antigenic sin is not impacting immunity to the targeted, heterologous epitopes.
In the present study, we focused on one particular set of epitopes that are conserved among pathogenic arenaviruses to provide proof of principle that such HLA class I-restricted epitopes exist in nature and that they can be used to induce cross-protective immunity to heterologous arenavirus challenge. However, in our ongoing efforts to identify HLA-restricted epitopes from pathogenic arenaviruses, we have found additional HLA-A2 and HLA-A3 supertype-restricted epitopes that are either (i) completely homologous in primary sequence among one or more pathogenic arenaviruses (n ϭ 1) or (ii) highly conserved (differing in primary sequence from one virus to another by 1 to 2 amino acid residues) and crossreactive among several pathogenic arenaviruses (n ϭ 4) (28) . In addition to our findings, ter Meulen et al. have shown that CD4 ϩ T cells from patients previously exposed to LASV are able to cross-reactively recognize epitopes derived from MOPV (51) . There are also many examples of HLA-restricted epitopes that are conserved/cross-reactive among multiple species of viruses, including viruses within the Hantavirus genus (24, 52) and Flaviviridae family (37, 38, 55) . Therefore, our strategy for multivalent vaccination may be applicable beyond the arenavirus family. Indeed, members of our team have recently shown that HLA-restricted CD4 ϩ T-cell epitopes that are conserved among pathogenic influenza virus strains exist and that they too are protective (2) .
In addition to having utility as vaccine determinants, the cross-reactive epitopes identified in this study also have value as diagnostic reagents. As we demonstrate in Fig. 1 , following an experimental infection with LCMV in HLA transgenic mice, peptides derived not only from the corresponding Old World virus LASV but also from the New World viruses GTOV and WWAV are recognized via an in vivo cytotoxicity assay. Sets of peptides such as this would be valuable tools for monitoring at-risk populations for arenavirus exposure, investigating the role of T cells in arenavirus pathogenesis in humans, and evaluating the capacity of new candidate vaccines to effectively induce cell-mediated immunity. One important consideration regarding our study is the fact that there is an incomplete overlap in the epitopes recognized by HLA transgenic mice and humans (27) . Therefore, it will be important to verify that the epitopes identified in the current study can indeed be recognized in HLA-A*0201-restricted humans following exposure to pathogenic arenaviruses.
In conclusion, we have demonstrated that HLA-restricted, cross-reactive epitopes exist among pathogenic arenaviruses and that individual epitopes can be utilized as effective vaccine determinants for multiple pathogenic arenaviruses. Because the epitopes in this study are HLA-A2 supertype restricted, they are capable of providing broad population coverage (ϳ43% of the population, regardless of ethnicity) (45) . Inclusion of cross-protective epitopes such as these in multivalent vaccine formulations will allow for a reduction in the complexity of the resulting vaccine. While the current study provides proof of concept for the proposed multivalent vaccination strategy, future studies to advance this approach will focus on the identification of other cross-protective epitopes that correspond to additional HLA supertype families and arenaviruses to increase coverage of both HLA backgrounds and pathogenic arenavirus species.
